Newbury Pharmaceuticals

Executive Summary

Newbury Pharmaceuticals is a hybrid pharmaceutical company based in Stockholm, Sweden, focused on the Nordic region with selective international sales. Founded in 2021, the company operates as both a marketing authorization holder and a specialized commercial partner, building a diversified portfolio across multiple therapeutic areas through in-licensing and exclusive distribution agreements. Its mission is to bring high-quality, value-creating medicines and technologies to patients in the Nordics. While still in early stages with no disclosed pipeline or revenue, Newbury's asset-light model and focus on a stable, high-value market position it for potential growth. The company's success hinges on its ability to secure attractive licenses and navigate regulatory pathways efficiently. Given its early stage and lack of public catalysts, the conviction is moderate, pending demonstration of execution.

Upcoming Catalysts (preview)

• Q3 2026Securing first in-licensing deal60% success
• Q4 2026Expansion into new therapeutic area40% success
• Q1 2027Announcement of first commercial partnership50% success